SCHEMBL1666083

SCHEMBL1666083

Nc1ncnc2c1N(CO)CN2[C@@H]1O[C@H](CO)C(O)C1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 2/20 0.52
HSPA8 P11142 2/20 0.52
DOT1L Q8TEK3 3/20 0.50
MAPK1 P28482 3/20 0.50
HIF1A Q16665 2/20 0.50
STAT6 P42226 2/20 0.50
DPP4 P27487 1/20 0.50
MEN1 O00255 1/20 0.50
SLC28A1 O00337 1/20 0.50
MAP3K7 O43318 1/20 0.50
SLC28A2 O43868 1/20 0.50
GAPDH P04406 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA2B P29275 1/20 0.50
ADORA1 P30542 1/20 0.50
PI4KA P42356 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PI4K2B Q8TCG2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28844518 0.99 HSPA5 (0.51) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL1665379 0.92 HSPA5 (0.51) HSPA5HSPA8DOT1LMAPK1HIF1A
Ammonia Solution, Strong SCHEMBL28147967 0.91 HSPA5 (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL1101261 0.86 HSPA8 (0.46) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL7617155 0.86 HTR1D (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL724943 0.86 MAPK1 (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL1936249 0.86 ADK (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL15973691 0.86 ADK (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL3841527 0.86 DOT1L (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A
SCHEMBL830795 0.86 MAPK1 (0.50) HSPA5HSPA8DOT1LMAPK1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3670523-B1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND THEIR USE IN METHODS FOR NUCLEIC ACID SEQUENCING AGILENT TECHNOLOGIES INC (US) 2021-08-11 EP disclosed
US-11001886-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing AGILENT TECHNOLOGIES, INC. (US) 2021-05-11 US disclosed
EP-3670523-A1 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING Agilent Technologies, Inc. (US) 2020-06-24 EP disclosed
EP-2755984-B1 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING AGILENT TECHNOLOGIES INC (US) 2020-02-12 EP disclosed
US-20190127790-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING AGILENT TECHNOLOGIES, INC. 2019-05-02 US disclosed
US-10041115-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing LASERGEN, INC. (US) 2018-08-07 US disclosed
EP-2307565-B1 REVERSIBLE NUCLEOSIDES AND NUCLEOTIDES TERMINATORS AND THEIR USE IN DNA SEQUENCING LASERGEN INC (US) 2017-11-29 EP disclosed
US-20170327886-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING LASERGEN, INC. (US) 2017-11-16 US disclosed
US-9689035-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing LASERGEN, INC. (US) 2017-06-27 US disclosed
US-20160369336-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING LASERGEN, INC. (US) 2016-12-22 US disclosed
EP-2755984-A1 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING Lasergen, Inc. (US) 2014-07-23 EP disclosed
US-20140051848-A1 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2014-02-20 US disclosed
US-8497360-B2 Nucleotides and nucleosides and methods for their use in DNA sequencing LASERGEN, INC. (US) 2013-07-30 US disclosed
US-20130122489-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING AGILENT TECHNOLOGIES, INC. 2013-05-16 US disclosed
WO-2013040257-A1 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING LASERGEN, INC. (US) 2013-03-21 WO disclosed
US-20130035237-A1 Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing AGILENT TECHNOLOGIES, INC. 2013-02-07 US disclosed
US-8148503-B2 Nucleotides and nucleosides and methods for their use in DNA sequencing LASERGEN, INC. (US) 2012-04-03 US disclosed
EP-2307565-A2 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING Lasergen, Inc. (US) 2011-04-13 EP disclosed
US-20100041041-A1 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2010-02-18 US disclosed
WO-2009152353-A2 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041041-A1 NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING UNG, NT5C2, NT5E HSPA5 3914/4885HSPA8 2841/4885DOT1L 1308/4885
US-20190127790-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING RNGTT, NT5C3B, NSUN2 HSPA5 3672/4885HSPA8 2502/4885DOT1L 1697/4885
US-10041115-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing RNGTT, NT5C3B, NSUN2 HSPA5 3636/4885HSPA8 2446/4885DOT1L 1685/4885
US-11001886-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing RNGTT, NT5C3B, NSUN2 HSPA5 3636/4885HSPA8 2446/4885DOT1L 1685/4885
US-20170327886-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING RNGTT, NT5C3B, NSUN2 HSPA5 3672/4885HSPA8 2502/4885DOT1L 1697/4885
US-20160369336-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING RNGTT, NT5C3B, NSUN2 HSPA5 3672/4885HSPA8 2502/4885DOT1L 1697/4885
US-20130035237-A1 Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing UNG, NT5C2, NT5E HSPA5 3914/4885HSPA8 2841/4885DOT1L 1308/4885
US-20130122489-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING RNGTT, NT5C3B, NSUN2 HSPA5 3672/4885HSPA8 2502/4885DOT1L 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.